A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients

被引：0
|
作者：
Lee, Valerie
Wang, Judy
El Khoueiry, Anthony
Verheul, Henk
Gootjes, Elske
Sharma, Anup
Kerner, Zachary
Jones, Peter
Baylin, Stephen
Lilly, Ellen
Ahuja, Nita
Brown, Thomas
Azad, Nilofer
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-CT017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT017
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium
    Sharma, M.
    Wroblewski, K.
    Kozloff, M.
    Modi, S. S.
    Sleckman, B. G.
    Taber, D.
    Vokes, E. E.
    Stadler, W. M.
    Polite, B. N.
    Kindler, H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [42] Phase I/II study of capecitabine(C)/oxaliplatin(O)/ irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Ou, K.
    Liu, X.
    Ma, X.
    Gao, L.
    Wang, Q.
    Yang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1514 - S1514
  • [43] A phase II trial of capecitabine (X) and irinotecan (I), in a biweekly schedule, for patients (Pts) with advanced/metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Gonzalez-Arenas, C
    Gonzalez-Flores, E
    Molina, M
    Muñoz, A
    Abad, G
    Garcia-Adrian, S
    Lopez, P
    Belon, J
    Perez-Manga, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 290S - 290S
  • [44] A phase I/II study of combination therapy of S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer
    Choi, Y.
    Kim, T.
    Lee, S.
    Lee, J.
    Chang, H.
    Kim, H.
    Shin, J.
    Lee, J.
    Kang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Phase II study of biweekly cetuximab (C) and irinotecan (I) as a second-line regimen for metastatic colorectal cancer (mCRC)
    Carneiro, B. A.
    Bahary, N.
    Lembersky, B.
    Fakih, M.
    Krishnamurthi, S. S.
    Lancaster, S.
    Pinkerton, R.
    Crandall, T.
    Potter, D.
    Ramanathan, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study
    Ciardiello, F.
    Salvatore, L.
    Cascinu, S.
    Sobrero, A.
    Banzi, M.
    Barone, C.
    Spallanzani, A.
    Latiano, T. L.
    Amatu, A.
    Zagonel, V.
    Biglietto, M.
    Di Costanzo, F.
    Di Bartolomeo, M.
    Santoro, A.
    Russo, A.
    Moscovici, M.
    Van Cutsem, E.
    Zaniboni, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 37 - 37
  • [47] A phase I/II study of hyaluronan derivitised irinotecan (HYCAMP™) in patients with metastatic colorectal cancer
    Gibbs, Peter
    Brown, Tracey
    Jennens, Ross
    Ng, Raymond
    Cinc, Edith
    Papadimitriou, John
    Carter, Chris
    Fox, Richard
    ANNALS OF ONCOLOGY, 2004, 15 : 105 - 105
  • [48] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Hidekazu Kuramochi
    Masayuki Ando
    Michio Itabashi
    Go Nakajima
    Kazuyuki Kawakami
    Mie Hamano
    Eiichi Hirai
    Hajime Yokomizo
    Ryuji Okuyama
    Tatsuo Araida
    Kazuhiko Yoshimatsu
    Shingo Kameoka
    Kazuhiko Hayashi
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 579 - 585
  • [49] Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer
    Tang, Patricia A.
    Cohen, Steven J.
    Kollmannsberger, Christian
    Bjarnason, Georg
    Virik, Kiran
    MacKenzie, Mary J.
    Lourenco, Lillian
    Wang, Lisa
    Chen, Alice
    Moore, Malcolm J.
    CLINICAL CANCER RESEARCH, 2012, 18 (21) : 6023 - 6031
  • [50] A phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab
    Nakajima, Go
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Lino, Takayuki
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER RESEARCH, 2016, 76
12345